scholarly journals Clozapine-Induced Pericardial Effusion Presenting with Persistent Tachycardia

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Nathan Gilbreth ◽  
Hari Nath ◽  
Fernando Quesada ◽  
Delatre Lolo

Clozapine is an atypical antipsychotic used in refractory schizophrenia and depression. Its use is often complicated by its vast side-effect profile including cardiovascular reactions, agranulocytosis, and seizures. Specifically, the cardiac complications of clozapine have been shown to predominantly cause myocarditis and pericarditis. In this case report, the case of a 58-year-old male being treated for treatment-resistant depression and schizophrenia who suffers from tachycardia is presented. He is treated empirically for orthostatic hypotension with IV fluids without much success. Further imaging and echocardiography demonstrated a pericardial effusion, a rare reaction (≤1 : 10000) that has only been documented in a handful of case reports. This anecdotal evidence highlights the significance of polyserositis/pericardial effusion in the context of clozapine-induced orthostatic hypotension resistant to rehydration. When starting a patient on clozapine, it is important to consider further workup and monitoring with laboratory baseline biomarkers and cardiac evaluation with symptomatic individuals. Upon immediate cessation of clozapine, the pericardial effusion should spontaneously resolve without complication and should not be rechallenged.

2018 ◽  
pp. 447-469
Author(s):  
S. Nassir Ghaemi

Seventeen case reports are provided applying the principles described in this volume, including the following triad of principles: 1. Treat diseases, not symptoms. 2. Do not use DSM-based diagnoses. 3. Focus on the course of the illness, not just its symptoms, when you are making diagnoses. In addition, specific pharmacological aspects of medications as used in practice are explored in the context of specific cases—mood illnesses; PTSD; personality states; purported ADD; seasonality in affective illness; stopping antidepressants for “depression”; first depression in a young adult; pre-adolescent depression versus bipolar illness; when benzodiazepines are preferable to SRIs for anxiety; hyperthymia misdiagnosed as treatment-resistant depression; premenstrual mood dysphoric disorder; low-dose divalproex for misdiagnosed narcissistic personality disorder; suicidality and antidepressants in borderline personality—and more.


2020 ◽  
Vol 42 (1) ◽  
pp. 92-101
Author(s):  
Stephanie Zakhour ◽  
Antonio E. Nardi ◽  
Michelle Levitan ◽  
Jose Carlos Appolinario

Abstract Objective To conduct a systematic review of literature on use and efficacy of cognitive-behavioral therapy (CBT) for treatment of treatment-resistant depression in adults and adolescents. Methods We performed a systematic review according to the Prisma Guidelines of literature indexed on the PubMed, SciELO, Psychiatry Online, Scopus, PsycArticles, Science Direct and the Journal of Medical Case Reports databases. Randomized controlled trials, open studies and case reports were included in the review. Results The searches returned a total of 1,580 articles, published from 1985 to 2017. After applying the inclusion criteria, 17 articles were selected, their complete texts were read and 8 were included in this review. Four of these studies were randomized controlled trials with adults, one of which covered a post-study follow-up period; two were randomized controlled trials with adolescents, one of which presented follow-up data; one was an open study; and one was a case report. The studies provide good quality and robust evidence on the topic addressed. Conclusions A combination of CBT with pharmacotherapy for treatment-resistant patients shows a decrease in depressive symptoms. CBT can be an effective type of therapy for adults and adolescents with treatment-resistant depression.


Sign in / Sign up

Export Citation Format

Share Document